Study validates that Great Basin’s assay provides cost effective, rapid and definitive detection of Shiga Toxin-producing E.coli

Salt Lake City, February 3, 2017 – Great Basin Scientific, Inc., a molecular diagnostics company, today announced the Journal of Clinical Microbiology published results of a study analyzing the sensitivity and cost effectiveness of the Great Basin Shiga Toxin Direct Test in detecting Shiga Toxin-producing Escherichia coli (STEC) from stool specimens. The results of the study demonstrate an advancement in STEC detection, concluding that the molecular assay from Great Basin provides clinicians with a more cost-effective, rapid and definitive patient diagnosis, when compared to culture and EIA methods, enabling physicians to make more timely decisions on the appropriate course of treatment.

“Reducing the cost and labor associated with testing stool culture specimens—generally one of the most expensive and labor intensive tests for hospitals and labs—is providing significant value to our hospital administrator and lab director customers,” said Rob Jenison, chief technology officer and senior vice president of R&D at Great Basin Scientific. “The study also determined that the superior sensitivity and more rapid turnaround time, when compared to routine culture methods, aids in infection control efforts and identification of potential outbreaks 24 to 72 hours sooner.”

Led by Dr. Blake W. Buchan from the Department of Pathology at The Medical College of Wisconsin, MI, the study found that Great Basin’s Shiga Toxin Direct Test was 93.2 percent sensitive and 99.3 percent specific for detection of stx1 and stx2, and 95.7 percent sensitive and 99.3 percent specific for detection of E.coli serotype O157. Based on the data from this analysis, culture and EIA-based methods for detection of STEC are only 33 percent sensitive when compared to molecular tests. The total time to result for Great Basin’s Shiga Toxin Direct Test is approximately two hours, compared to approximately 36 to 48 hours for culture-based methods. Great Basin’s Shiga Toxin Direct Test is priced relative to common culture and Enzyme Immunoassay tests, at $24 per test, and provides a cost savings from routine stool culture when accounting for the total material and labor involved. Furthermore, the study concluded that Great Basin’s Shiga Toxin Direct Test increases the positive identification of Shiga Toxin-producing E.coli by three to four times, when compared to similar test panels.

The Great Basin Shiga Toxin Direct Test is the only stand-alone test to meet the Center for Disease Control’s recommendations for the identification of high-virulence serotype O157 in conjunction with detection of STEC. The Company announced the commercial launch of the Shiga Toxin Direct Test in August 2016, and the test also has CE mark designation under the European Directive of In Vitro Diagnostic Medical Devices.

Great Basin Scientific’s molecular diagnostics system offers low-plex (one to three analytes), mid-plex (four to six analytes) and multiplex (syndromic) testing, with commercial assays available for the detection of STEC, Group B Streptococcus (GBS), Toxigenic Clostridium difficile (C. diff), and a Staph Blood Culture Panel for identifying bloodstream infections caused by MRSA and other Staphylococcus species. Continuing the Company’s efforts to expand its menu of sample-to-result assays to diagnose infectious disease, Great Basin Scientific has five additional tests on their product roadmap, including a Stool Bacterial Pathogens Panel and a Bordetella Direct Test, both of which recently completed clinical trials and have been submitted to the U.S. Food & Drug Administration (FDA) for 510(k) clearance; and a Nasal S. aureus Pre-surgical Screen, Candida Blood Infections Panel, and CT/NG Test, which are currently in development.

About Great Basin Scientific

Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies.  The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company’s vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company’s website at